-
1
Gut-lung microbiome dysbiosis is significantly linked to interstitial lung diseases (ILD), influencing inflammation and immune dysregulation.
-
2
Idiopathic pulmonary fibrosis (IPF) shows altered lung microbiome diversity, correlating with disease progression and mortality.
-
3
Fungal dysbiosis in sarcoidosis may serve as a biomarker, indicating the need for further research on its role in disease progression.
-
4
Gut dysbiosis is implicated in connective tissue-associated ILDs, with probiotics and high-fiber diets showing protective effects.
-
5
Traditional Chinese medicine, specifically Gand-du-quing decoction, may improve lung function by regulating lung microbiome and inflammation.
